UPDATE – Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies (Summary of changes)

Authors

  • Andrea Kokorovic Centre Hospitalier de l’Université de Montréal
  • Alan I. So Department of Urological Sciences, University of British Columbia
  • Hosam Serag Department of Urological Sciences, University of British Columbia
  • Christopher French Division of Urology, Department of Surgery, Memorial University
  • Robert J. Hamilton Division of Urology, Department of Surgery, Princess Margaret Cancer Centre
  • Jason P. Izard Department of Urology, Queen’s University
  • Jasmir G. Nayak Section of Urology, Department of Surgery, University of Manitoba
  • Frédéric Pouliot CHU de Quebec, Université Laval
  • Fred Saad Centre Hospitalier de l’Université de Montréal
  • Bobby Shayegan Division of Urology, Departments of Surgery and Oncology, McMaster University
  • Armen Aprikian McGill University Health Centre
  • Ricardo A. Rendon Department of Urology, Dalhousie University

DOI:

https://doi.org/10.5489/cuaj.8007

Keywords:

ADT, prostate cancer, CVD risk

Downloads

Download data is not yet available.

Downloads

Published

2022-07-21

How to Cite

Kokorovic, A. ., So, A. I. ., Serag, H. ., French, C. ., Hamilton, R. J. ., Izard, J. P. ., Nayak, J. G. ., Pouliot, F. ., Saad, F. ., Shayegan, B. ., Aprikian, A. ., & Rendon, R. A. . (2022). UPDATE – Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies (Summary of changes). Canadian Urological Association Journal, 16(8), 243–4. https://doi.org/10.5489/cuaj.8007

Issue

Section

CUA Guideline